베타
임상 레이더 AI
임상시험 NCT06018194은(는) 관상동맥 질환에 대해 모집중 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요.
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰

ELUCIDATE FFRct Study

모집중
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '시험 설명하기'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT06018194은(는) 관상동맥 질환에 대해 알아보는 관찰연구입니다. 현재 상태는 모집중이며, 연구는 2023년 9월 1일에 시작되어 350명의 참여자를 모집하고 있습니다. Elucid Bioimaging Inc.이(가) 진행하며, 2024년 7월 31일까지 완료될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2024년 2월 20일에 갱신되었습니다.
간단한 개요
The goal of this study is to evaluate the diagnostic accuracy of a novel plaque-based coronary CT angiography (CCTA) fractional flow reserve (FFRct) software device for the estimation of invasive fractional flow reserve (FFR).

Researchers will compare the Elucid plaque-based FFRct analysis to invasively measured FFR in patients who have previously undergone CCTA and invasively assessed FFR.

상세한 설명
Invasive fractional flow reserve is a clinically validated measure of lesion-specific ischemia and is preferred over visual estimation of diameter stenosis for clinical decision-making regarding coronary revascularization in patients with stable clinical presentations. Fractional flow reserve derived from coronary computed tomography angiography (FFRct) using computational fluid dynamic (CFD)-based software has been shown to be a reasonably accurate estimate of invasive FFR and is included in contemporary guidelines as a decision-tool for management of patients with intermediate stenosis on CCTA. However, CFD-based FFRct is calculated based predominately on detailed coronary lumen geometry. It is understood that the burden and type of coronary atherosclerosis, in addition to lumen geometry, significantly impacts the vasodilatory capacity of the coronary endothelium.

Preliminary studies suggest that invasive FFR can be accurately estimated based on the quantification of coronary plaque burden and the assessment of plaque composition. Previously, the investigators have demonstrated that a novel plaque-based FFRct approach, using a histologically validated software (ElucidVivoTM) for the measurement of plaque morphology (volume, plaque risk characteristics, and stenosis) to train a deep-learning model, was shown to be accurate and superior to lumen stenosis for predicting invasive FFR in a single-site feasibility study.

In this study, the investigators seek to assess the diagnostic accuracy of the Elucid plaque-based FFRct software to estimate invasive FFR in patients at multiple centers.

공식 제목

The ELUCIDATE FFRct Study

질환/상태
관상동맥 질환
출판물
이 임상 시험에 대해 발표된 과학 논문 및 연구 자료.
기타 연구 식별자
  • 3-ST-03-03
NCT 번호
실제 연구 시작일
2023-09-01
최신 업데이트 게시
2024-02-20
예상 연구 완료일
2024-07-31
계획된 등록 인원
350
연구종류
관찰연구
상태
모집중
키워드
coronary computed tomographic angiography
coronary CTA
cardiac CT
fractional flow reserve
plaque
시험군 / 개입
참가자 그룹/시험군개입/치료
Low FFR
Invasive FFR \<= 0.80
Elucidvivo
Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)
High FFR
Invasive FFR \> 0.80
Elucidvivo
Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)
주요결과변수
결과변수측정값 설명시간 범위
Sensitivity of FFRct versus invasive FFR for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Specificity of FFRct versus invasive FFR for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
이차결과변수
결과변수측정값 설명시간 범위
Sensitivity of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Specificity of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Area under the receiver-operating characteristic curve (AUC) of FFRct for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Area under the receiver-operating characteristic curve (AUC) of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Accuracy of FFRct for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Accuracy of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Negative predictive value of FFRct for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Negative predictive value of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Positive predictive value of FFRct for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Positive predictive value of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
적격성 기준

연령대
성인, 노인
최소 연령
18 Years
참여 가능한 성별
전체

- Adults >=18 years with at least one 30-90% stenosis on CCTA (>64- detector row) performed within 60 days of undergoing invasive FFR.

  • History of coronary revascularization with coronary artery bypass graft (CABG) surgery and/or percutaneous coronary intervention (PCI) (stent or balloon angioplasty) prior to CCTA and invasive FFR.
  • History of myocardial infarction prior to CCTA and invasive FFR.
  • Known complex congenital heart disease.
  • Existing pacemaker or internal defibrillator lead implantation(s).
  • Existing prosthetic heart valve.
  • Absence of CCTA Digital Imaging and Communications in Medicine (DICOM) data for analysis.
  • Absence of invasive coronary angiography imaging or adequate description defining the position of the invasive FFR wire location.
  • Poor CCTA image quality that does not meet Elucid image processing requirements for plaque and FFRct.
  • Absence of study date for CCTA or invasive FFR.
  • Interval clinical myocardial infarction, diagnosis of decompensated heart failure, stroke, or coronary revascularization procedure between CCTA and invasive FFR.
  • Non-diagnostic CCTA or invasive FFR. Studies where the results of the study were deemed non-diagnostic for clinical decision-making will be excluded.
  • CCTA or invasive FFR studies performed prior to 1 January 2016.
Elucid Bioimaging Inc. logoElucid Bioimaging Inc.
Lundquist Institute at Harbor-UCLA Medical Center logoLundquist Institute at Harbor-UCLA Medical Center
연구 대표 연락처
연락처: Todd C Villines, MD, 978-468-0508, [email protected]
연락처: John Aluru, MBBS, 978-468-0508, [email protected]
9 1개국에 임상시험 장소

California

Cardiovascular Medical Group of Southern California, Beverly Hills, California, 90210, United States
Ronald P Karlsberg, MD, 연락처
대상자모집전

Georgia

Piedmont Healthcare, Atlanta, Georgia, 30309, United States
Venkateshwar Polsani, MD, 연락처
대상자모집전

Indiana

Parkview Health, Fort Wayne, Indiana, 46845, United States
Dustin Thomas, MD, 연락처
대상자모집전

Kansas

Midwest Heart and Vascular Specialists, Overland Park, Kansas, 66211, United States
Stephen A Bloom, MD, 연락처
모집중

New Jersey

Valley Health System, Ridgewood, New Jersey, 07450, United States
Himanshu Gupta, MD, 연락처
대상자모집전

Ohio

Cleveland Clinic, Cleveland, Ohio, 44195, United States
Milind Desai, MD, MBA, 연락처
대상자모집전

Tennessee

Centennial Heart, Nashville, Tennessee, 37203, United States
David Huneycutt, MD, 연락처
대상자모집전
Ascension Medical Group, Nashville, Tennessee, 37205, United States
Andrew O Zurich, MD, 연락처
대상자모집전

Virginia

University of Virginia, Charlottesville, Virginia, 22908, United States
Patricia Rodriguez-Lozano, MD, 연락처
모집중